Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-MSLN/anti-CD3 bispecific antibody ZW171

A bispecific T-cell engager (TCE) and bispecific antibody directed against both the tumor-associated antigen (TAA) mesothelin (MSLN) and the T-cell surface antigen CD3, with potential immunostimulating and antineoplastic activities. Upon administration, anti-MSLN/anti-CD3 bispecific antibody ZW171 bivalently binds to MSLN expressed on tumor cells and monovalently binds to CD3 expressed on cytotoxic T lymphocytes (CTLs). This activates and redirects CTLs to MSLN-expressing tumor cells, which results in the CTL-mediated death of MSLN-expressing tumor cells. MSLN, a cell surface glycoprotein involved in cell adhesion, is overexpressed in a variety of cancer cell types.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:anti-mesothelin/anti-CD3 bispecific antibody ZW171
anti-MSLN/CD3 T-cell engaging bispecific antibody ZW171
MSLN x CD3 2 +1 bispecific antibody ZW171
MSLN-targeting T-cell engager ZW171
TCE ZW171
Code name:ZW 171
ZW-171
ZW171
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search